Home » News and events » Scientific innovation is crucial, but it’s only part of the AMR response

Scientific innovation is crucial, but it’s only part of the AMR response

Articles

18–24 November is World AMR Awareness Week, a global campaign to raise awareness of antimicrobial resistance (AMR). The theme for 2026 is ‘One Health, One Action: Prevent AMR Now’, calling on everyone to do their part. Throughout the week, we’re highlighting how, at LifeArc, we’re playing our part in addressing this complex global health challenge.

There is no doubt that drug-resistant infections are now an urgent global health threat. It is estimated that more than 1 million people already die from bacterial AMR each year1, and by 2050, it is predicted to be linked to more than 8 million deaths each year, directly causing close to 2 million of them2. 

Resistance is rising at an alarming rate – 1 in 6 laboratory-confirmed bacterial infections worldwide are resistant to one or more antibiotic drug3. The world will need a range of scientific innovation to transform the whole landscape: how infections are prevented, diagnosed, how resistance develops, and how they’re treated. The response to AMR is not limited to discovering more antibiotics. 

Encouragingly, we are seeing progress in AMR innovation emerging across therapeutics, prevention, diagnostics and surveillance, including technological advances such as artificial intelligence (AI). Many innovators and organisations, including LifeArc, are now putting strategic efforts into progressing early-stage science, advancing clinical innovation and helping to create a more diverse and resilient innovation pipeline to address drug-resistant infections.  

Picking up the PACE of innovations 

The clinical antibacterial pipeline now includes 90 candidates in development4, but improvements in the pipeline have been incremental – only two of the 13 new antibiotics approved between 2017 and 2024 were truly innovative compared to existing drug classes5. Recognising that there are still significant gaps in the AMR innovation pipeline, LifeArc, together with Innovate UK and Medicines Discovery Catapult, set up PACE (Pathways to Antimicrobial Clinical Efficacy). PACE is a £30 million initiative supporting promising innovative, early phase drug discovery and diagnostic projects.  

Blending investment with scientific, translational and sector expertise and capabilities, PACE offers wrap-around support alongside funding, connects the AMR ecosystem and removes barriers to innovation. This includes expanding access to clinically relevant bacterial strains in partnership with the UK Health Security Agency, giving researchers and innovators access to reliable, well-characterised strains for testing. 

Now in its third year, PACE has supported a range of projects that collectively address the world’s most threatening pathogens. The latest PACE-funded projects will be announced throughout this World AMR Awareness Week, adding more promising innovations to the preclinical pipeline for AMR. 

Diagnosing accurately and early enough

Alongside new antimicrobial treatments, innovative diagnostics are another essential piece of the AMR puzzle, enabling healthcare workers to make informed prescribing decisions and preventing unnecessary antibiotic use. Without timely and accurate diagnostic tools, even the most promising new treatments could lose their effectiveness rapidly.

People with cystic fibrosis (CF) experience a buildup of thick mucus in the lungs, trapping bacteria and leading to persistent infections. Current tests often fail to detect these infections early or accurately, allowing chronic infection to develop and threatening lung function and quality of life of people with CF. Adding to the challenges they face are the narrowing treatment options and increasing antibiotic resistance.  

To help overcome these barriers for the CF community, we formed the CF AMR Syndicate with Medicines Discovery Catapult and Cystic Fibrosis Trust. By connecting expertise across sectors, the syndicate aims to get more CF antimicrobials and diagnostics to the clinic, faster. Informed by over 150 stakeholders in the CF community including people living with CF, healthcare professionals and diagnostic innovators, the syndicate developed a suite of diagnostic target product profiles (TPPs) for managing CF lung infections. The TPPs are now available to researchers and the wider community to help them shape the future direction of diagnostics innovation.  

Making innovations accessible and affordable 

Even the best diagnostics and treatments cannot make an impact if patients cannot access them or are priced out of them. One way to make treatments more affordable is through lowering the cost of manufacturing. LifeArc and the Gates Foundation are jointly supporting seven projects exploring innovative manufacturing technologies to reduce the cost of producing monoclonal antibodies.  

Beyond uses in disease areas such as cancer, monoclonal antibodies have great potential to prevent and treat infectious diseases safely and precisely. Unlike antibiotics, they may be less prone to developing drug resistance, can provide immediate protection, and have faster development timelines. Despite their promise in addressing drug-resistant infections, antibodies remain largely inaccessible in low-resource settings, as manufacturing costs range from $50-100 per gram. The cost of antibodies for infectious disease needs to be driven down to around $10 per gram to achieve ‘vaccine-like’ pricing, for these invaluable treatments to be accessible and affordable for everyone across the globe, especially communities most impacted by drug-resistant infections. 

Translating innovation into real-world impact 

Research and development cannot happen in silos. We need close collaboration among researchers, innovators, healthcare providers, policymakers, funders and other stakeholders within the AMR ecosystem. By working together, we will be able to strengthen the infrastructure, clinical pathways and health systems needed to turn scientific progress into meaningful improvements for people affected by drug-resistant infections. 

1 Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis – ScienceDirect.
2 Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050 – ScienceDirect. 3 Global antibiotic resistance surveillance report 2025. 4 Analysis of antibacterial agents in clinical and preclinical development: overview and analysis 2025. 5 WHO releases report on state of development of antibacterials.


Media contact

Hannah Perlin

Senior Manager, PR & Media